Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Clinical trial NCT05999604 · RECRUITING
Trial details
- NCT number
- NCT05999604
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-09
- Primary completion
- 2029-11-01
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.